20S Proteasome-IN-2 

20S Proteasome-IN-2 is a human 20S proteasome inhibitor. 20S Proteasome-IN-2 shows high selectivity to its β5 subunit with the IC₅₀ of 0.18 μM. 20S Proteasome-IN-2 displays anti-proliferative effect in vitro and in vivo, and arrests cell cycle at G2/M^[1].

IC50: 0.18 μM (β5 subunit of 20S Proteasome)

20S Proteasome-IN-2 (compoun 11m) inhibits 20S proteasome by forming no irreversible covalent modification on it^[1].
20S Proteasome-IN-2 (compoun 11m) (1.56, 3.13, 6.25, 12.5, and 25 μM) shows high binding affinity with purified human 20S proteasome, the equilibrium dissociation constants is 4.8 μM^[1].
20S Proteasome-IN-2 (compoun 11m) (0-1.5 μM; 24 hours) inhibits tumor cells in a low concerntration with IC₅₀ values of 0.88, 0.77, 0.67, 0.73, 1.3, 0.57, and 0.28 μM for A375, BGC-823, Hela, HT-29, A549, PCM1E8, HCT-116, resepectively^[1].
20S Proteasome-IN-2 (compoun 11m) (0-1.5 μM; 24 hours) arrests the cell cycle at G2/M^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

20S Proteasome-IN-2 (compoun 11m) is (i.v.; 5 mg/kg; single injection) rapidly cleared from the plasma with an average terminal plasma half-life of 14 min, thus it exhibits extensive tissue permeability and low clearance rate (CL) of 2.0 L/h/k, and is largely eliminated extrahepatically^[1].
20S Proteasome-IN-2 (compoun 11m) (i.v.; 10 mg/kg; twice one week; 4 weeks) shows antitumor efficacy combat solid tumors^[1].
Pharmacokinetic parameters of 20S Proteasome-IN-2 (compoun 11m)^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

620.76

C₃₀H₄₄N₄O₈S

2028300-31-2

O=C(N[C@@H](COC)C(N[C@@H](CC(C)C)C(C1=CC=CO1)=O)=O)[C@@H](NS(=O)(C2=CC=C(C)C=C2)=O)CC(NCC(C)(C)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sun Q, et al. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome. Eur J Med Chem. 2020 Apr 15. 192:112160.  [Content Brief]